WallStSmart

Bruker Corporation (BRKR)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1802% more annual revenue ($65.77B vs $3.46B). MRK leads profitability with a 13.6% profit margin vs -0.3%. BRKR appears more attractively valued with a PEG of 1.52. MRK earns a higher WallStSmart Score of 50/100 (D+).

BRKR

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 5.0Quality: 5.5
Piotroski: 3/9Altman Z: 1.71

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BRKRUndervalued (+4.9%)

Margin of Safety

+4.9%

Fair Value

$44.60

Current Price

$56.53

$11.93 discount

UndervaluedFair: $44.60Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$119.60

$38.64 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRKR0 strengths · Avg: 0/10

No standout strengths identified

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

BRKR4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BRKR

BRKR has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BRKR

The primary concerns for BRKR are PEG Ratio, Revenue Growth, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

BRKR profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

BRKR carries more volatility with a beta of 1.30 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bruker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?